Precipio, Inc. (PRPO)
USD 5.45
(4.01%)
USD 5.45
(4.01%)
| Year | Eps | Eps Growth |
|---|---|---|
| 2023 | -4.51 USD | 57.97% |
| 2022 | -10.73 USD | -32.47% |
| 2021 | -8.10 USD | 45.42% |
| 2020 | -14.84 USD | 68.09% |
| 2019 | -46.51 USD | 78.65% |
| 2018 | -217.81 USD | 83.72% |
| 2017 | -1338.20 USD | 99.16% |
| 2016 | -158.45 Thousand USD | -558.3% |
| 2015 | -24.07 Thousand USD | -2774.87% |
| 2014 | -837.26 USD | 15.44% |
| 2013 | -990.09 USD | -53.11% |
| 2012 | -646.66 USD | 39.58% |
| 2011 | -1070.24 USD | -211.41% |
| 2010 | -343.68 USD | -63.05% |
| 2009 | -210.78 USD | -287.89% |
| 2008 | -54.34 USD | 76.51% |
| 2007 | -231.31 USD | 38.6% |
| 2006 | -376.70 USD | 83.4% |
| 2005 | -2268.92 USD | 64.55% |
| 2004 | -6399.55 USD | -26.39% |
| 2003 | -5063.52 USD | -3.5% |
| 2002 | -4892.37 USD | -176.12% |
| 2001 | -1771.85 USD | 37.01% |
| 2000 | -2812.93 USD | 31.1% |
| 1999 | -4082.63 USD | 0.0% |
| Year | Eps | Eps Growth |
|---|---|---|
| 2024 Q2 | -0.83 USD | 43.15% |
| 2024 Q1 | -1.46 USD | -324.62% |
| 2023 Q1 | -2.62 USD | -29.7% |
| 2023 FY | - USD | 57.97% |
| 2023 Q4 | 0.65 USD | 162.5% |
| 2023 Q3 | -1.04 USD | 44.68% |
| 2023 Q2 | -1.88 USD | 28.24% |
| 2022 Q2 | -1.63 USD | 57.55% |
| 2022 FY | - USD | -32.47% |
| 2022 Q3 | -2.74 USD | -68.1% |
| 2022 Q4 | -2.02 USD | 26.28% |
| 2022 Q1 | -3.84 USD | -97.94% |
| 2021 FY | - USD | 45.42% |
| 2021 Q2 | -2.86 USD | -75.46% |
| 2021 Q3 | -1.64 USD | 42.66% |
| 2021 Q4 | -1.94 USD | -18.29% |
| 2021 Q1 | -1.63 USD | -31.45% |
| 2020 Q2 | -3.96 USD | 48.3% |
| 2020 FY | - USD | 68.09% |
| 2020 Q3 | -4.13 USD | -4.29% |
| 2020 Q4 | -1.24 USD | 69.98% |
| 2020 Q1 | -7.66 USD | 24.38% |
| 2019 FY | - USD | 78.65% |
| 2019 Q1 | -9.60 USD | 85.48% |
| 2019 Q2 | -20.91 USD | -117.81% |
| 2019 Q3 | -6.13 USD | 70.68% |
| 2019 Q4 | -10.13 USD | -65.25% |
| 2018 Q1 | -58.18 USD | 80.52% |
| 2018 FY | - USD | 83.72% |
| 2018 Q4 | -66.11 USD | -32.83% |
| 2018 Q3 | -49.77 USD | -21.54% |
| 2018 Q2 | -40.95 USD | 29.61% |
| 2017 FY | - USD | 99.16% |
| 2017 Q1 | -1175.45 USD | -2317.13% |
| 2017 Q2 | -1898.86 USD | -61.54% |
| 2017 Q4 | -298.70 USD | -17.81% |
| 2017 Q3 | -253.54 USD | 86.65% |
| 2016 Q2 | -696.23 USD | 51.84% |
| 2016 Q4 | -48.63 USD | 96.34% |
| 2016 FY | - USD | -558.3% |
| 2016 Q1 | -1445.53 USD | -237.58% |
| 2016 Q3 | -1328.28 USD | -90.78% |
| 2015 Q3 | -238.65 USD | -96.74% |
| 2015 FY | - USD | -2774.87% |
| 2015 Q2 | -121.30 USD | 16.75% |
| 2015 Q1 | -145.70 USD | 55.79% |
| 2015 Q4 | -428.21 USD | -79.43% |
| 2014 Q2 | -238.24 USD | 6.77% |
| 2014 FY | - USD | 15.44% |
| 2014 Q1 | -255.55 USD | -4.87% |
| 2014 Q4 | -329.58 USD | -6626.12% |
| 2014 Q3 | -4.90 USD | 97.94% |
| 2013 FY | - USD | -53.11% |
| 2013 Q4 | -243.68 USD | 28.28% |
| 2013 Q2 | -175.45 USD | 23.89% |
| 2013 Q3 | -339.76 USD | -93.65% |
| 2013 Q1 | -230.52 USD | -55.03% |
| 2012 Q3 | -207.58 USD | -389.11% |
| 2012 Q4 | -148.69 USD | 28.37% |
| 2012 Q2 | -42.44 USD | 81.73% |
| 2012 Q1 | -232.27 USD | -1125.02% |
| 2012 FY | - USD | 39.58% |
| 2011 Q4 | 22.66 USD | 116.3% |
| 2011 Q3 | -139.04 USD | 78.84% |
| 2011 Q2 | -657.03 USD | -115.89% |
| 2011 Q1 | -304.34 USD | -262.18% |
| 2011 FY | - USD | -211.41% |
| 2010 Q3 | -98.39 USD | 21.77% |
| 2010 Q4 | -84.03 USD | 14.59% |
| 2010 Q2 | -125.77 USD | -253.58% |
| 2010 FY | - USD | -63.05% |
| 2010 Q1 | -35.57 USD | -351.2% |
| 2009 FY | - USD | -287.89% |
| 2009 Q1 | -104.62 USD | -335.19% |
| 2009 Q4 | 14.16 USD | 135.24% |
| 2009 Q3 | -40.18 USD | 49.86% |
| 2009 Q2 | -80.14 USD | 23.4% |
| 2008 Q2 | 11.09 USD | -17.18% |
| 2008 Q1 | 13.39 USD | -42.46% |
| 2008 Q3 | -54.78 USD | -593.96% |
| 2008 Q4 | -24.04 USD | 56.12% |
| 2008 FY | - USD | 76.51% |
| 2007 Q3 | -148.10 USD | -696.94% |
| 2007 Q1 | -131.30 USD | -14.87% |
| 2007 FY | - USD | 38.6% |
| 2007 Q4 | 23.27 USD | 115.71% |
| 2007 Q2 | 24.81 USD | 118.9% |
| 2006 Q4 | -114.30 USD | 38.36% |
| 2006 Q2 | -42.05 USD | -20.45% |
| 2006 Q3 | -185.42 USD | -340.95% |
| 2006 Q1 | -34.91 USD | 97.16% |
| 2006 FY | - USD | 83.4% |
| 2005 FY | - USD | 64.55% |
| 2005 Q2 | -157.41 USD | 69.78% |
| 2005 Q3 | 17.51 USD | 111.12% |
| 2005 Q4 | -1231.23 USD | -7131.58% |
| 2005 Q1 | -520.89 USD | 59.45% |
| 2004 Q2 | -2812.64 USD | -287.68% |
| 2004 Q3 | -1567.98 USD | 44.25% |
| 2004 Q4 | -1284.58 USD | 18.07% |
| 2004 FY | - USD | -26.39% |
| 2004 Q1 | -725.51 USD | 55.1% |
| 2003 Q2 | -1071.35 USD | -29.75% |
| 2003 Q3 | -1361.85 USD | -27.12% |
| 2003 Q4 | -1615.72 USD | -18.64% |
| 2003 Q1 | -825.72 USD | 61.43% |
| 2003 FY | - USD | -3.5% |
| 2002 Q2 | -907.25 USD | -18.3% |
| 2002 Q4 | -2140.62 USD | -96.9% |
| 2002 Q1 | -766.89 USD | -21.84% |
| 2002 FY | - USD | -176.12% |
| 2002 Q3 | -1087.17 USD | -19.83% |
| 2001 Q4 | -629.43 USD | -41.47% |
| 2001 FY | - USD | 37.01% |
| 2001 Q1 | -287.02 USD | -203.08% |
| 2001 Q2 | -395.49 USD | -37.79% |
| 2001 Q3 | -444.91 USD | -12.5% |
| 2000 FY | - USD | 31.1% |
| 2000 Q1 | -1452.62 USD | 0.0% |
| 2000 Q2 | -1124.99 USD | 22.55% |
| 2000 Q3 | -589.51 USD | 47.6% |
| 2000 Q4 | -94.70 USD | 83.94% |
| 1999 FY | - USD | 0.0% |
| Name | Eps | Eps Difference |
|---|---|---|
| Aclaris Therapeutics, Inc. | -1.27 USD | -255.118% |
| Applied DNA Sciences, Inc. | -15.21 USD | 70.348% |
| Aspira Women's Health Inc. | -1.81 USD | -149.171% |
| Biodesix, Inc. | -0.64 USD | -604.688% |
| BioNexus Gene Lab Corp. | -0.17 USD | -2552.941% |
| bioAffinity Technologies, Inc. | -0.91 USD | -395.604% |
| bioAffinity Technologies, Inc. | -0.91 USD | -395.604% |
| Bionano Genomics, Inc. | -6.81 USD | 33.774% |
| CareDx, Inc | -3.54 USD | -27.401% |
| Check-Cap Ltd. | -3.00 USD | -50.333% |
| Castle Biosciences, Inc. | -2.14 USD | -110.748% |
| DarioHealth Corp. | -1.93 USD | -133.679% |
| Exact Sciences Corporation | -1.13 USD | -299.115% |
| Fulgent Genetics, Inc. | -5.63 USD | 19.893% |
| Guardant Health, Inc. | -4.28 USD | -5.374% |
| ICON Public Limited Company | 7.46 USD | 160.456% |
| IDEXX Laboratories, Inc. | 10.17 USD | 144.346% |
| Illumina, Inc. | -7.35 USD | 38.639% |
| Intelligent Bio Solutions Inc. | -6.38 USD | 29.31% |
| iSpecimen Inc. | -1.23 USD | -266.667% |
| Standard BioTools Inc. | -0.94 USD | -379.787% |
| MDxHealth SA | -1.66 USD | -171.687% |
| 23andMe Holding Co. | -1.40 USD | -222.143% |
| Medpace Holdings, Inc. | 9.20 USD | 149.022% |
| Myriad Genetics, Inc. | -1.39 USD | -224.46% |
| Mainz Biomed B.V. | -1.62 USD | -178.395% |
| ENDRA Life Sciences Inc. | -1.11 USD | -306.306% |
| NeoGenomics, Inc. | -0.70 USD | -544.286% |
| Neogen Corporation | -0.04 USD | -10267.816% |
| Inotiv, Inc. | -4.10 USD | -10.0% |
| Natera, Inc. | -3.78 USD | -19.312% |
| OpGen, Inc. | -41.47 USD | 89.125% |
| OPKO Health, Inc. | -0.25 USD | -1704.0% |
| Psychemedics Corporation | -0.72 USD | -526.389% |
| Prenetics Global Limited | -5.58 USD | 19.176% |
| Prenetics Global Limited | -5.58 USD | 19.176% |
| Personalis, Inc. | -2.25 USD | -100.444% |
| RadNet, Inc. | 0.05 USD | 9515.449% |
| Sera Prognostics, Inc. | -1.16 USD | -288.793% |
| Sotera Health Company | 0.18 USD | 2605.556% |
| Neuronetics, Inc. | -1.05 USD | -329.524% |
| Star Equity Holdings, Inc. | 7.42 USD | 160.782% |
| Star Equity Holdings, Inc. | 7.42 USD | 160.782% |
| Trinity Biotech plc | -3.14 USD | -43.631% |
| T2 Biosystems, Inc. | -19.19 USD | 76.498% |
| Twist Bioscience Corporation | -3.60 USD | -25.278% |
| Exagen Inc. | -1.34 USD | -236.567% |